Summary:
Subjects with benign prostatic hypertrophy, not being benefited with current available therapy, will be given this novel injectable therapy and evaluate the benefits.
Qualified Participants Must:
• Subjects aged 45 to 75yrs inclusive
• Able to sign informed consent
• Have documented history of BPH for atleast one year
• Have stopped any BPH medications for atleast 30 days prior to recieving this novel therapy
Qualified Participants May Receive:
Compensated for time and travel.